Clinical Trial Update: Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

View source ↗

Summary

A completed clinical study reports successful treatment of Netherton syndrome with a combination of secukinumab and dupilumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Netherton Syndrome

Drugs mentioned

• Cosentyx (secukinumab)
• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Neterton Syndrome | Status: COMPLETED